McKesson Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian S. Tyler
- Full Time Employees
- 42,300
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 6555 State Highway 161 Irving TX United States of America 75039
- IPO Date
- Nov 10, 1994
- CIK
- 0000927653
- Website
- mckesson.com
- Similar Companies
- Business
- McKesson Corporation (NYSE: MCK) operates as a diversified healthcare services company, primarily engaged in pharmaceutical distribution, medical-surgical supply distribution, oncology and multispecialty solutions, and prescription technology services. The company distributes pharmaceuticals and medical supplies through its North American Pharmaceutical segment, which serves retail and community pharmacies, specialty care settings, and health systems across the United States and Canada via a network of distribution centers; its Oncology and Multispecialty segment provides practice management, technology solutions, specialty drug distribution, clinical trial services, group purchasing, and pharmacy solutions for community-based oncology practices and providers in retina and ophthalmology; its Medical-Surgical Solutions segment merchandises and distributes more than 285,000 national brand products alongside McKesson's own brands of medical-surgical supplies, pharmaceuticals, laboratory equipment, and supplies to physician offices, surgery centers, long-term care providers, home health agencies, health systems, government facilities, and online retailers in the United States; and its Prescription Technology Solutions segment offers medication access, affordability, and adherence programs, including prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support connecting patients, pharmacies, providers, payers, and biopharma companies. [fetch:https://www.mckesson.com/about-us/business-segments/] Founded in 1833 and headquartered in Irving, Texas, McKesson serves healthcare providers, pharmacies, biopharma manufacturers, governments, and consumers primarily in North America, with additional distribution and retail operations in Norway, which it agreed to sell in August 2025. [fetch:https://www.mckesson.com/about-us/history/] In recent strategic developments, McKesson acquired a controlling interest in Community Oncology Revitalization Enterprise Ventures (Core Ventures), associated with Florida Cancer Specialists & Research Institute, for $2.49 billion in August 2024 to bolster oncology care; welcomed Florida Cancer Specialists as a member of The US Oncology Network; acquired a controlling interest in PRISM Vision Group to expand into ophthalmology and retina care; formed a joint venture between US Oncology Research and HCA Healthcare's Sarah Cannon Research Institute to advance oncology research and clinical trials; and announced in September 2025 a corporate restructuring into four segments—North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—effective fiscal 2026, alongside plans to separate the Medical-Surgical Solutions segment and updated long-term growth targets including 13% to 16% adjusted earnings per share growth. [fetch:https://www.mckesson.com/about-us/history/]
Here's Why McKesson (MCK) is a Strong Momentum Stock
McKesson Q1 Earnings Call Highlights
McKesson: Solid Q1 Earnings And Management Execution (Rating Upgrade)
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why
MCK Stock Up as Q1 Earnings Beat on Specialty Growth, Guidance Raised
MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise
Why McKesson (MCK) is a Top Growth Stock for the Long-Term
Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night.
McKesson Corp (MCK) (Q1 2027) Earnings Call Highlights: Robust Revenue Growth and Raised Guidance Signal Strong Momentum
McKesson Corporation (MCK) Q1 2027 Earnings Call Transcript
McKesson (MCK) Q1 Earnings and Revenues Top Estimates
McKesson (MCK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
McKesson raises annual profit forecast on strong growth in specialty drug business
McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
What's in Store for These 4 Healthcare Companies This Earnings Season?
Why McKesson (MCK) is a Top Value Stock for the Long-Term
Can AI-Driven Efficiency and Specialty Demand Boost MCK's Q1 Results?
Curious about McKesson (MCK) Q1 Performance? Explore Wall Street Estimates for Key Metrics
McKesson (MCK) Stock Dips While Market Gains: Key Facts